Journal Articles Citing CryoStor CS10® Recently Added to BioLife Solutions’ Evidence Library

Multiple Uses for CryoStor in Cell Manufacturing Journal articles recently added to BioLife Solutions’ Evidence Library illustrate several stages during the cell manufacturing process for which CryoStor CS10® cryopreservation solution is applicable. The three articles that follow include several different cell types cryopreserved in CryoStor CS10. An expanded list of cell types biopreserved in BioLife…

Read More

Journal Articles Citing Cryopreservation Component Recently Added to BioLife Solutions’ Evidence Library

Cryopreservation adds flexibility to timelines when working with cells. In the case of cellular therapies, that can mean initial flexibility to schedule patient cell collection, transport cells to the manufacturing facility and initiate manufacturing. Cryopreservation of the final cell therapy product adds flexibility to be able to schedule the return of cells to the patient…

Read More

BioLife Solutions Named one of the Fastest Growing Companies in North America on Deloitte’s 2019 Technology Fast 500™

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, recently announced that based on revenue growth from 2015 to 2018, it has been selected for inclusion on the Deloitte 2019 Technology Fast 500 list. Mike Rice, BioLife President and CEO, commented, “We…

Read More

Joining Forces!

BioLife Solutions issued a press release August 8, 2019, announcing the execution of a share exchange agreement to purchase the remaining 56% of shares of SAVSU Technologies that BioLife did not previously own. BioLife’s relationship with Savsu spans six years, during the development and growth of the evo® Cold Chain 2.0™ system, encompassing evo® hardware…

Read More

BioLife Solutions to Acquire SAVSU Technologies

We’re Joining Forces! BioLife Solutions announces intent to purchase SAVSU Technologies shares outstanding. On July 8, 2019, BioLife issued a press release announcing that the company will purchase the remaining 56% of shares of SAVSU that BioLife does not presently own.  The acquisition is expected to close within 45 days. BioLife’s relationship with SAVSU spans…

Read More

Could not attend? BioLife Solutions’ Posters Presented During ISCT 2019 International Meeting in Melbourne

Posters presenting data for T-cells cryopreserved in CryoStor® cryopreservation solution, authored by BioLife Solutions’ Alireza Abazari, Ph.D., Scientific Applications Director and Aby J. Mathew, Ph.D., Senior Vice President & Chief Technology Officer, were featured during the International Society for Cell & Gene Therapy meeting in Melbourne, Australia, May 29 – June 1, 2019. View the…

Read More


Implementation of Biopreservation Best Practices to Address a Critical Component of Cell & Gene Therapy Manufacturing Hosted by Cell and Gene Therapy Insights Implementation of best practices in formulation can directly address multiple process bottlenecks including: GMP compliance, minimizing freezing damage, support stability during storage and against transient warming events, support post-thaw stability, and excipient…

Read More

Privacy Preference Center